- BioPharma Services, a Healwell AI (TSX:AIDX) subsidiary specializing in early-phase clinical trials, is expanding into late stage patient trials
- BioPharma is integrating Canadian Phase Onward, a dedicated clinical research site built within the framework of Healwell’s polyclinic family and specialty medicine facility
- By integrating this late-stage trial expertise, the company can now offer comprehensive clinical trial services from early-phase to late-stage, enhancing its service offerings to its clients
- Healwell AI stock last traded at C$1.45 per share
BioPharma Services, a Healwell AI (TSX:AIDX) subsidiary specializing in early-phase clinical trials, is expanding into late stage patient trials.
BioPharma is integrating Canadian Phase Onward, a dedicated clinical research site built within the framework of Healwell’s polyclinic family and specialty medicine facility. By integrating this late-stage trial expertise, the company can now offer comprehensive clinical trial services from early-phase to late-stage, enhancing its service offerings to its clients.
This is a significant achievement that can boost BioPharma’s capacity to oversee clinical trials throughout all stages of drug development, potentially transforming the company into a comprehensive contract research organization. This step also aligns with Healwell’s broader goal of expanding clinical research capabilities and leveraging synergies across its business sectors to foster growth and innovation in healthcare.
“BioPharma is an industry leader in early phase trials and integrating them with our Canadian Phase Onward division immediately leverages our synergies to create a more robust and complete end-to-end platform for life science customers,” Healwell’s CEO, Alexander Dobranowski, said in a news release. “Given Healwell’s access to significant patient populations, we have a unique opportunity to leverage our AI capabilities to efficiently find at-risk patients in need of access to clinical research. BioPharma is our clinical research engine and has a strong competency and track record in first conducting early-stage trials in drug development, followed by Canadian Phase Onward, which expands BioPharma’s abilities into late-stage patient trials. Through these integrations, Healwell can now leverage AI to participate meaningfully across all stages of drug development, bringing immense value potential to at-risk patients and life science partners.”
BioPharma will also integrate with Healwell AI’s data science and AI platform to enhance research and development, disease detection and patient identification capabilities, accelerating patient trials in turn.
Since its inception, BioPharma has conducted more than 2,200 clinical trials with around 250 pharmaceutical clients worldwide, including four of the top 25 largest pharmaceutical companies globally.
Healwell is a healthcare technology company applying AI and data science to preventative care.
Healwell AI stock (TSX:AIDX) last traded at C$1.45 per share and has risen 93.33 per cent since the year began.
Join the discussion: Find out what everybody’s saying about cancer research and this healthcare AI stock on the Healwell AI Inc. Bullboard, and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo, generated by AI: Adobe Stock)